Dual Specificity Mitogen Activated Protein Kinase Kinase 1-Europe Market Status and Trend Report 2013-2023
Report Summary
Dual Specificity Mitogen Activated Protein Kinase Kinase 1-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Dual Specificity Mitogen Activated Protein Kinase Kinase 1 industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 2013-2017, and development forecast 2018-2023
Main market players of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in Europe, with company and product introduction, position in the Dual Specificity Mitogen Activated Protein Kinase Kinase 1 market
Market status and development trend of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by types and applications
Cost and profit status of Dual Specificity Mitogen Activated Protein Kinase Kinase 1, and marketing status
Market growth drivers and challenges
The report segments the Europe Dual Specificity Mitogen Activated Protein Kinase Kinase 1 market as:
Europe Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
RG-7304
E-6201
Selumetinib Sulfate
Others
Europe Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Clinic
Hospital
Others
Europe Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market: Players Segment Analysis (Company and Product introduction, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales Volume, Revenue, Price and Gross Margin):
Array BioPharma Inc.
AstraZeneca Plc
Eisai
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck & Co., Inc.
Merck KGaA
Novartis AG
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Dual Specificity Mitogen Activated Protein Kinase Kinase 1-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Dual Specificity Mitogen Activated Protein Kinase Kinase 1 industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 2013-2017, and development forecast 2018-2023
Main market players of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in Europe, with company and product introduction, position in the Dual Specificity Mitogen Activated Protein Kinase Kinase 1 market
Market status and development trend of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by types and applications
Cost and profit status of Dual Specificity Mitogen Activated Protein Kinase Kinase 1, and marketing status
Market growth drivers and challenges
The report segments the Europe Dual Specificity Mitogen Activated Protein Kinase Kinase 1 market as:
Europe Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
RG-7304
E-6201
Selumetinib Sulfate
Others
Europe Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Clinic
Hospital
Others
Europe Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market: Players Segment Analysis (Company and Product introduction, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales Volume, Revenue, Price and Gross Margin):
Array BioPharma Inc.
AstraZeneca Plc
Eisai
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck & Co., Inc.
Merck KGaA
Novartis AG
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE
1.1 Definition of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in This Report
1.2 Commercial Types of Dual Specificity Mitogen Activated Protein Kinase Kinase
1.2.1 RG-7304
1.2.2 E-6201
1.2.3 Selumetinib Sulfate
1.2.4 Others
1.3 Downstream Application of Dual Specificity Mitogen Activated Protein Kinase Kinase
1.3.1 Clinic
1.3.2 Hospital
1.3.3 Others
1.4 Development History of Dual Specificity Mitogen Activated Protein Kinase Kinase
1.5 Market Status and Trend of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 2013-2023
1.5.1 EMEA Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market Status and Trend 2013-2023
1.5.2 Regional Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA 2013-2017
2.2 Consumption Market of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Regions
2.2.1 Consumption Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Regions
2.2.2 Revenue of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Regions
2.3 Market Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Regions
2.3.1 Market Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in Europe 2013-2017
2.3.2 Market Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in Middle East 2013-2017
2.3.3 Market Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in Africa 2013-2017
2.4 Market Development Forecast of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA 2018-2023
2.4.1 Market Development Forecast of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA 2018-2023
2.4.2 Market Development Forecast of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Types
3.1.2 Revenue of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Downstream Industry
4.2 Demand Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Downstream Industry in Major Countries
4.2.1 Demand Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Downstream Industry in Europe
4.2.2 Demand Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Downstream Industry in Middle East
4.2.3 Demand Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Downstream Industry in Africa
4.3 Market Forecast of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE
5.1 EMEA Economy Situation and Trend Overview
5.2 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Downstream Industry Situation and Trend Overview
CHAPTER 6 DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE 1 MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Major Players
6.2 Revenue of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Major Players
6.3 Basic Information of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Major Players
6.3.1 Headquarters Location and Established Time of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Major Players
6.3.2 Employees and Revenue Level of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE 1 MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Array BioPharma Inc.
7.1.1 Company profile
7.1.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.1.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of Array BioPharma Inc.
7.2 AstraZeneca Plc
7.2.1 Company profile
7.2.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.2.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of AstraZeneca Plc
7.3 Eisai
7.3.1 Company profile
7.3.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.3.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of Eisai
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Company profile
7.4.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.4.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
7.5 GlaxoSmithKline Plc
7.5.1 Company profile
7.5.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.5.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc
7.6 Merck & Co., Inc.
7.6.1 Company profile
7.6.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.6.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.7 Merck KGaA
7.7.1 Company profile
7.7.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.7.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of Merck KGaA
7.8 Novartis AG
7.8.1 Company profile
7.8.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.8.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of Novartis AG
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE
8.1 Industry Chain of Dual Specificity Mitogen Activated Protein Kinase Kinase
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE
9.1 Cost Structure Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase
9.2 Raw Materials Cost Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase
9.3 Labor Cost Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase
9.4 Manufacturing Expenses Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase
CHAPTER 10 MARKETING STATUS ANALYSIS OF DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in This Report
1.2 Commercial Types of Dual Specificity Mitogen Activated Protein Kinase Kinase
1.2.1 RG-7304
1.2.2 E-6201
1.2.3 Selumetinib Sulfate
1.2.4 Others
1.3 Downstream Application of Dual Specificity Mitogen Activated Protein Kinase Kinase
1.3.1 Clinic
1.3.2 Hospital
1.3.3 Others
1.4 Development History of Dual Specificity Mitogen Activated Protein Kinase Kinase
1.5 Market Status and Trend of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 2013-2023
1.5.1 EMEA Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market Status and Trend 2013-2023
1.5.2 Regional Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA 2013-2017
2.2 Consumption Market of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Regions
2.2.1 Consumption Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Regions
2.2.2 Revenue of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Regions
2.3 Market Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Regions
2.3.1 Market Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in Europe 2013-2017
2.3.2 Market Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in Middle East 2013-2017
2.3.3 Market Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in Africa 2013-2017
2.4 Market Development Forecast of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA 2018-2023
2.4.1 Market Development Forecast of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA 2018-2023
2.4.2 Market Development Forecast of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Types
3.1.2 Revenue of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Downstream Industry
4.2 Demand Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Downstream Industry in Major Countries
4.2.1 Demand Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Downstream Industry in Europe
4.2.2 Demand Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Downstream Industry in Middle East
4.2.3 Demand Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Downstream Industry in Africa
4.3 Market Forecast of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE
5.1 EMEA Economy Situation and Trend Overview
5.2 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Downstream Industry Situation and Trend Overview
CHAPTER 6 DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE 1 MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Major Players
6.2 Revenue of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 in EMEA by Major Players
6.3 Basic Information of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 by Major Players
6.3.1 Headquarters Location and Established Time of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Major Players
6.3.2 Employees and Revenue Level of Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE 1 MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Array BioPharma Inc.
7.1.1 Company profile
7.1.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.1.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of Array BioPharma Inc.
7.2 AstraZeneca Plc
7.2.1 Company profile
7.2.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.2.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of AstraZeneca Plc
7.3 Eisai
7.3.1 Company profile
7.3.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.3.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of Eisai
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Company profile
7.4.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.4.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
7.5 GlaxoSmithKline Plc
7.5.1 Company profile
7.5.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.5.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc
7.6 Merck & Co., Inc.
7.6.1 Company profile
7.6.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.6.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.7 Merck KGaA
7.7.1 Company profile
7.7.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.7.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of Merck KGaA
7.8 Novartis AG
7.8.1 Company profile
7.8.2 Representative Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Product
7.8.3 Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Sales, Revenue, Price and Gross Margin of Novartis AG
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE
8.1 Industry Chain of Dual Specificity Mitogen Activated Protein Kinase Kinase
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE
9.1 Cost Structure Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase
9.2 Raw Materials Cost Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase
9.3 Labor Cost Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase
9.4 Manufacturing Expenses Analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase
CHAPTER 10 MARKETING STATUS ANALYSIS OF DUAL SPECIFICITY MITOGEN ACTIVATED PROTEIN KINASE KINASE
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
